Mach One Completes Acquisition of Veterinary Diagnostic Company, VDx, Inc.

LAS VEGAS -- Mach One Corporation (PINK SHEETS:MNCN) announces the acquisition of VDx, Inc., a diagnostics and solutions company which specializes in Immune or Gamma Globulin testing (IgG) for the equine and bovine markets. VDx currently markets and sells specialized tests for bovine IgG, NEFA for the dairy industry, Equine IgG, and a failure of passive transfer test recently acquired from a division of Bioqual, Inc. (FPT).

VDx's products include Lyphomune(TM), a product acquired from Bioqual and used in the treatment of failure of passive transfer (FPT) as well as ImmunoGam(TM) and MiniGam(TM). FPT occurs in newborn foals and calves when antibodies are transferred in insufficient amounts from the mother's colostrums. Lyphomune(TM) is used as a colostrums replacement, supplement and prophylactic, in sterile powder form, and can be administered orally or intravenously.

Weymann Cheng, Director of Mach One stated, "VDx has already made a significant impact within the dairy cattle industry with their diagnostics and nutritional supplement programs to maximize output for the dairy farmer. With the addition of the BioQual suite of products, we expect VDx to broaden its market in the field of IgG colostrum replacement. We are thrilled to have finally found a company that can have a great impact on not only Mach One's success in the future, but perhaps to make our world a healthier place to live."

"VDx is in final production of its IgG colostrums replacement product for the nine million dairy calves born each year," said Monte Tobin, President of VDx, Inc. "This product will help stop the spread of mastitis and Johne's disease (paratuberculosis) - a high priority disease for the U.S. cattle industry- to calves through the mother's colostrums. This replacement product can be used as a time saving management tool for large dairies that have as many as 15 to 50 calves being born each day throughout a year. With the strength of being a public entity now, and with the addition of the suite of colostral products acquired from BioQual, VDx is in a great position to broaden its reach into the 1.1 billion dollar Immune Deficiency Disease market."

Prior to the acquisition, Mach One had no operations, and was actively seeking an acquisition candidate. It issued 30 million shares, representing 90% of its outstanding stock, for VDx. VDx will be a wholly owned subsidiary of Mach One and operate out of its Belgium, Wisconsin facility.

Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.

Mach One Corporation (PINK SHEETS:MNCN)